Approval of two more vaccines for fighting against COVID: Would these be sufficient ? (GS Paper II) Source : The Hindu , Indian Express 

Approval of two more vaccines for fighting against COVID: Would these be sufficient ? (GS Paper II) Source : The Hindu , Indian Express 

Approval of two more vaccines for fighting against COVID: Would these be sufficient ?  Today Current Affairs

Context : India has approved two more covid-19 vaccines and the antiviral drug under emergency use authorisation, Union health minister Mansukh Mandaviya told the nation .

Introduction : 

From the mid of December , the cases of coronavirus agins have started to increase in India . In this festive week of December because of inappropriate covid behavior these cases are continuously increasing . Therefore , our scientist and the government are jointly trying to fight agist this virus scientifically. Two new vaccines Coebevax and Covovax  and one pill Monupiravir are approved in this sequence 

What is CorbeAux : This is a vaccine is developed by hyderabad based Biological E Limited and the Baylor College of Medicine in Houston, US and the US company Dynavax Technologies This is a protein subunit vaccine  which means that instead of whole virus , it uses fragmented iof it to trigger an immune response . In this case this subunit contains a harmless S protein . Once the immune system recognise the proteins , it will produce antibodies to fight against that protein 

The efficiency of this Pill is good as per the clinical trial data . It can also neutralize the delta virus . Its effectiveness is more than 80 % . It has also conducted Phase III active comparator clinical trials to evaluate if this vaccine is superior to Covishield . In the pivotal phase of immunogenic superiority it demonstrated superior immune response in comparison with Covid Shield when assessed for neutralizing Antibody Geomatic Means titers against the Ancestral Wuhan Strain and the globally dominant Delta variant 

What is CovoVax : The Hindu Analysis

Covovax is produced by Serum Institute of India under license from Novavax, a US based biotechnology company. This vaccine has also been approved by the World Health Organization (WHO) under its emergency use .. 

On the basis of trials of 3 phases it showed its efficiency of 96.4 % against the original virus strain, 86.3% against Alpha and 89.7 % efficiency overall. After its trial in the US and Mexico that demonstrated 100 % protection against moderate and severe disease and 90.4 % efficiency overall 

Molnupiravir : This is also approved by US Food and Drug administration , close on the heels of paxlovid by Pfizer Inc, is said to be a promising drug for those with mild and moderate disease and also easily administered as a pill . Molnupiravir comes in 200 mg pills ; the recommendation in India is for 800 mg twice daily for 5 days . In india will will be manufactured by 13 drug makers like Dr Reddy Natco, MSN, hetero, Optimus, Aurobindo, Mylan, Cipla Sun Pharma , Torrent , BDR, Stride and Pune based Emcure . 

The drug regulator of the UK covered its effectiveness . It did not authorize this pill   for use of more than 5 consec=cutive days , or a patient younger than 18 as it may affect bone and cartilage growth . In India , this is recommended for those patients who are adults and have an oxygen level over 93 % and who have a high risk progression of the disease . 

Conclusion: The Hindu Analysis

Therefore we can conclude on the basis of the above description, we should fight with coronavirus through scientific research and by improving our health system . Besides the duty of our scientist and government we should also follow the instruction of the government and we should follow the covid appropriate behavior to sight with covid . 

 

In this article we mention all information about Approval of two more vaccines for fighting against COVID: Would these be sufficient ?  Today Current Affairs

plutus ias daily current affairs 29 December 2021

No Comments

Post A Comment